Wednesday, August 16, 2017

EyewireTV — Solar Eclipse Safety; Eyetube3D Launches

As Americans prepare for the first total solar eclipse in the United States in 37 years, EyewireTV provides tips on how to safely view the rare event and advice to physicians who may see patients with solar retinopathy; and a year after launching in the United States, Shire applies for European approval for its blockbuster dry eye drug lifitegrast. Also, Eyetube announces the launch of Eyetube3D, a new channel that allows physicians with a virtual reality headset to view 3-dimensional surgical cases online.

Watch Video

Wednesday, August 02, 2017| Cataract, FDA Approval/Clearance, Guardian Health Sciences, Intravitreal Injection, Photocoagulation, Quantel Medical

EyewireTV — FDA Safety Alert for Intravitreal Compounded Drug; Easyret Approved in US

In this week’s EyewireTV, the FDA issues a safety alert after at least 43 patients who received intravitreal injections of a compounded drug from Guardian Pharmacy Services in Dallas suffered serious adverse events; and a recent study published in JAMA Ophthalmology reveals that high vitamin K1 intake reduces cataract formation in an elderly Mediterranean population. Also, Quantel Medical receives FDA approval for the Easyret fully integrated 577-nm yellow photocoagulator, which is used to treat certain forms of macular edema and peripheral retinal pathologies.

Watch Video

Wednesday, July 26, 2017| Dompé, Dry Eye, neurotrophic keratitis, TearLab Corp., TearLab Discovery System

EyewireTV - Dry Eye Disease Redefined; New TearLab Platform

In this week’s Eyewire, the Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) II report is published, updating the definition of dry eye disease; and TearLab receives CE Mark approval for its next-generation, in-vitro diagnostics testing platform, the TearLab Discovery System. Also, Dompé announces that the European Commission has granted marketing authorization of its cenegermin eye drops for the treatment of moderate to severe neurotrophic keratitis.

Watch Video

Wednesday, July 19, 2017| Alcon, Cataract Surgery, Contact Lenses & Solutions, Excimer Lasers, FDA Approval/Clearance, Hyperopia, Johnson & Johnson Vision Care, Novartis

EyewireTV — FDA Approves Hyperopia Indication for iDesign; Alcon Sales Increase

In this week’s EyewireTV, the FDA approves a new hyperopia treatment indication for Johnson & Johnson Vision’s Star S4 IR Excimer Laser System and iDesign System; and Alcon sales accelerate in the second quarter, which may have an impact on Novartis’ plans to spin-off the eye care division. Also, British surgeons find 27 contact lenses lodged in a woman’s eye while prepping her for cataract surgery.

Watch Video

Wednesday, July 12, 2017| Blepharoplasty, FDA Approval/Clearance, Glaucoma, Inotek Pharmaceuticals, Intraocular Pressure, IOP, IOPtima, Ocular Therapeutix

EyewireTV — FDA Rejects Dextenza Again; Blepharoplasty System Launched

In this week’s EyewireTV, for the second time, the FDA does not approve Ocular Therapeutix's NDA for Dextenza, citing manufacturing deficiencies; and IOPtima announces the launch of the iLid CO2 laser-assisted blepharoplasty kit. Also, in a phase 2 trial, Inotek Pharmaceuticals’ glaucoma candidate fails to show a clinical advantage in IOP reduction after 4 weeks.

Watch Video

Wednesday, July 05, 2017| , Argus II, FDA Approval/Clearance, Medicare, Second Sight Medical Products

EyewireTV — FDA to Fix Orphan Drug Backlog; Leafy Greens Improve Cognition

In this week’s EyewireTV, the FDA unveils a strategic plan to eliminate the agency’s existing orphan drug designation request backlog; and new research reveals that higher levels of retinal lutein and zeaxanthin are positively related to academic achievement in children. Also, Second Sight Medical Products announces the expansion of Medicare coverage for its Argus II Retinal Prosthesis System to 11 additional states and Washington DC.

Watch Video
Load More